Global Pharmaceuticals & Biotech Top Stock Picks from Analysts

Xencor

Market Cap: US$609.8m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.

VISEN Pharmaceuticals

Market Cap: HK$4.7b

An investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland.

Nxera Pharma

Market Cap: JP¥89.6b

Develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom.

Maravai LifeSciences Holdings

Market Cap: US$602.7m

A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.

AnaptysBio

Market Cap: US$590.5m

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.

Compass Therapeutics

Market Cap: US$578.2m

A clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.

Gossamer Bio

Market Cap: US$570.7m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

Oruka Therapeutics

Market Cap: US$560.6m

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Rapport Therapeutics

Market Cap: US$560.2m

Operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.

Arvinas

Market Cap: US$558.7m

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

aTyr Pharma

Market Cap: US$536.0m

A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.

Allergy Therapeutics

Market Cap: UK£381.3m

A commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders.

Esperion Therapeutics

Market Cap: US$510.1m

A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.

Zevra Therapeutics

Market Cap: US$501.3m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

I-Mab

Market Cap: US$500.2m

A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.

REGENXBIO

Market Cap: US$490.5m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

COMPASS Pathways

Market Cap: US$489.3m

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Formycon

Market Cap: €416.0m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

Evolus

Market Cap: US$485.8m

A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

Arcturus Therapeutics Holdings

Market Cap: US$484.7m

Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

ALT5 Sigma

Market Cap: US$483.5m

Provides blockchain-powered technologies worldwide.

Bicycle Therapeutics

Market Cap: US$483.1m

A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.

Opthea

Market Cap: AU$738.8m

A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

Eton Pharmaceuticals

Market Cap: US$479.2m

A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

Alumis

Market Cap: US$478.7m

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

PYC Therapeutics

Market Cap: AU$729.1m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Shin Nippon Biomedical Laboratories

Market Cap: JP¥70.6b

A contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally.

Verano Holdings

Market Cap: CA$633.1m

Operates as a vertically integrated multi-state cannabis operator in the United States.

Prime Medicine

Market Cap: US$445.7m

A biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States.

Olema Pharmaceuticals

Market Cap: US$435.8m

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

MBX Biosciences

Market Cap: US$434.0m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Solid Biosciences

Market Cap: US$433.0m

Develops therapies for neuromuscular and cardiac diseases in the United States.

XOMA Royalty

Market Cap: US$427.9m

Operates as a biotech royalty aggregator in the United States and the Asia Pacific.

Corvus Pharmaceuticals

Market Cap: US$427.0m

A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

Foresee Pharmaceuticals

Market Cap: NT$13.0b

Operates as biopharmaceutical company in the United States, China, and Europe.

Handa Pharmaceuticals

Market Cap: NT$13.0b

A specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States.